FDA panel votes to expand use of Vertex cystic fibrosis drug

(Reuters) - A U.S. Food and Drug Administration advisory panel on Tuesday voted 13-2 to recommend expanding approval of Vertex Pharmaceuticals Inc's cystic fibrosis drug Kalydeco to include a wider range of patients with the rare lung disease, the company said.

via Reuters: Health News Read More Here..